Successfully leading many commercial groups in the global market today is Scott Chaplin, who accepted the role of a Senior Business Advisor with Allozymes this month. Having spent the last 30 years in the managerial level of biotechnology and F&F industry, Scott has supported companies to drive a commercial value proposition in the industry with a strategic focus on revenue enhancement, new product and technology introductions, P/L assessments and competitive analysis across North America, Europe, China, etc, thus earning him the name ‘commercial expert’. But for a global presence like this, Scott would need to demystify the nuts and bolts of how to implement a high-growth approach to further drive opportunities and profitability, which was quite evidently achieved through his stretched and expanded global network.
Thus, Scott will be a truly great addition to the Allozymes family and will support Allozymes to expand in North America and Europe. What this means for Allozyme in 2021 though, is that we’ll continue seizing more opportunities in the synbio arena with our unique products and services, backed by our proprietary technologies and our expert team.
“I am excited to be a part of the Allozymes commercial leadership group to share their novel and ground-breaking technology to drive innovation and optimization for high value ingredients. We are seeing great interest and enthusiasm in their product services and new ingredient developments”, says Scott.
As for team Allozymes, we’re equally thrilled to see Scott apply his commercial experience and first-class consultations to help grow our business and reach our revenue goal for 2021 and beyond.
On behalf of all of us, welcome onboard!
